Toralizumab  (Synonyms: IDEC-131; Anti-Human CD40 ligand Recombinant Antibody)

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease^[1][2][3].

Toralizumab has prothrombotic properties in vitro that are mediated by crystallizable fragment (Fc)-gamma receptor IIa (FcγRIIa)-dependent platelet activation triggered by high-order immune complexes formed by anti-CD154 antibodies crosslinking soluble CD154^[4].
Toralizumab (Compound IDEC-131) (0-200 mcg/mL) modestly reduces lymphocyte proliferative responses when used alone in MLR and the reduction is not dose-dependent^[5].
Toralizumab blocks the CD62E expression induced by coincubating HEC with D1.1 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Toralizumab (Compound IDEC-131) (15-20 mg/kg/dose, i.v., day 0, 1, 3, 7 then weekly for 8 w) results in slightly longer survival than untreated monkeys^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.66 kDa

252662-47-8

Liquid

Colorless to light yellow

[Toralizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized CD40L/CD154/TRAP Protein, Human (His, HY-P72907) can bind Toralizumab. The EC₅₀ for this effect is 5.068 ng/mL.

• [1]. Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096.  [Content Brief]

  [2]. Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8.  [Content Brief]

  [3]. Murphy, G., & Isenberg, D. A. (2019). New therapies for systemic lupus erythematosus - past imperfect, future tense. Nature reviews. Rheumatology, 15(7), 403-412.  [Content Brief]

  [4]. Lassiter, G., et al., (2023). TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 23(8), 1171-1181.  [Content Brief]

  [5]. Xu, H., et al., (2003). Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. Journal of immunology (Baltimore, Md.: 1950), 170(5), 2776-2782.  [Content Brief]